Areteia Therapeutics Announces Positive Topline Results from the First Phase III Study of Oral Dexpramipexole in Eosinophilic Asthma
In the EXHALE-4 study, dexpramipexole met the primary endpoint with statistically significant improvement in lung function compared with placebo Dexpramipexole demonstrated statistically significant reduction in blood absolute eosinophil count (AEC) compared with placebo Full results will be presented at an upcoming … Continued